anti-MAG mAb (GlaxoSmithKline)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-MAG mAb (GlaxoSmithKline)

Drug Alias Nameanti-MAG monoclonal antibody (GlaxoSmithKline)anti-myelin associated glycoprotein mAb (GlaxoSmithKline)anti-MAG mAb (GSK/University of Pennsylvania/University of Washington/VA Medical Center Philadelphia)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody

Mechanisms of ActionNeuroprotectants

TargetsUpdating

Therapy Area/IndicationsBrain Injuries

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited Kingdom

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesGlaxosmithkline Plc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGlaxosmithkline Plc

Active IndicationsN/A

Inactive IndicationsBrain Injuries

Other Information

ATC CodeN/A